Evidence map›Paper›PMID 36626401›Full record

ArticlePLoS pathogens2023

Structure and neutralization mechanism of a human antibody targeting a complex Epitope on Zika virus.

Cameron Adams, Derek L Carbaugh, Bo Shu, Thiam-Seng Ng, Izabella N Castillo, Ryan Bhowmik, Bruno Segovia-Chumbez, Ana C Puhl, Stephen Graham, Sean A Diehl and 4 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Cameron AdamsDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Derek L CarbaughDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Bo ShuProgram in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore, Singapore.
Thiam-Seng NgProgram in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore, Singapore.
Izabella N CastilloDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Ryan BhowmikDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Bruno Segovia-ChumbezDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Ana C PuhlCenter for Integrative Chemical Biology and Drug Discovery, Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Stephen GrahamDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Sean A DiehlDepartment of Microbiology and Molecular Genetics, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America.
Helen M LazearDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Shee-Mei LokProgram in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore, Singapore.
Aravinda M de SilvaDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.ORCID 0000-0003-3317-5950
Lakshmanane PremkumarDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
University of North Carolina at Chapel Hill · USNational University of Singapore · SGUniversity of Vermont · US

Funding

T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Aravinda M. DeSilva · 2015 to 2026
$34.1M
Using Dengue Controlled Human Infection Model to Identify Adaptive Immune Correlates of ProtectionP20GM125498 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Ellen Kozelka · 2018 to 2026
$24.9M
Molecular Basis of Flavivirus Cross-Neutralization by Human AntibodiesR01AI107731 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESILVA, ARAVINDA M. · 2013 to 2022
$5.3M
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue VaccineU01AI141997 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Sean A. Diehl, Anna Palmer Durbin · 2019 to 2026
$5.1M
Molecular Biology of Viral Diseases Predoctoral Training GrantT32AI007419 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark T Heise, CARY A MOODY · 1993 to 2026
$4.7M
Protective Immune Mechanisms against Zika Virus Infection in the Female Reproductive TractR21AI144631 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LAZEAR, HELEN · 2019 to 2020
$422k
Upgrade of a FACS Aria Cell SorterS10OD018175 · OD · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BOYSON, JONATHAN E · 2015 to 2015
$153k
NIAID NIH HHS P01 AI106695NIAID NIH HHS R01 AI107731NIAID NIH HHS R21 AI144631NIAID NIH HHS T32 AI007419NIAID NIH HHS U01 AI141997NIGMS NIH HHS P20 GM125498NIH HHS S10 OD018175
6 · The paper itself

Abstract

We currently have an incomplete understanding of why only a fraction of human antibodies that bind to flaviviruses block infection of cells. Here we define the footprint of a strongly neutralizing human monoclonal antibody (mAb G9E) with Zika virus (ZIKV) by both X-ray crystallography and cryo-electron microscopy. Flavivirus envelope (E) glycoproteins are present as homodimers on the virion surface, and G9E bound to a quaternary structure epitope spanning both E protomers forming a homodimer. As G9E mainly neutralized ZIKV by blocking a step after viral attachment to cells, we tested if the neutralization mechanism of G9E was dependent on the mAb cross-linking E molecules and blocking low-pH triggered conformational changes required for viral membrane fusion. We introduced targeted mutations to the G9E paratope to create recombinant antibodies that bound to the ZIKV envelope without cross-linking E protomers. The G9E paratope mutants that bound to a restricted epitope on one protomer poorly neutralized ZIKV compared to the wild-type mAb, demonstrating that the neutralization mechanism depended on the ability of G9E to cross-link E proteins. In cell-free low pH triggered viral fusion assay, both wild-type G9E, and epitope restricted paratope mutant G9E bound to ZIKV but only the wild-type G9E blocked fusion. We propose that, beyond antibody binding strength, the ability of human antibodies to cross-link E-proteins is a critical determinant of flavivirus neutralization potency.

Indexed as

Zika VirusZika Virus InfectionAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCryoelectron MicroscopyEpitopesHumansProtein SubunitsViral Envelope ProteinsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesProtein SubunitsViral Envelope Proteins

Identifiers

PMID36626401
PMCPMC9870165
OpenAlexW4314949676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.